Menu
Search
|

Menu

Close
X

Veracyte Inc VCYT.OQ (NASDAQ Stock Exchange Global Market)

29.02 USD
+0.52 (+1.82%)
As of Jul 17
Previous Close 28.50
Open 28.55
Volume 168,189
3m Avg Volume 254,855
Today’s High 29.11
Today’s Low 28.23
52 Week High 30.25
52 Week Low 8.78
Shares Outstanding (mil) 47.01
Market Capitalization (mil) 1,339.76
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
30
FY18
92
FY17
72
FY16
65
EPS (USD)
FY19
-0.047
FY18
-0.642
FY17
-0.914
FY16
-1.106
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
13.20
8.16
Price to Book (MRQ)
vs sector
14.12
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
15.62
18.17
LT Debt to Equity (MRQ)
vs sector
15.34
13.01
Return on Investment (TTM)
vs sector
-18.67
12.64
Return on Equity (TTM)
vs sector
-27.67
17.19

EXECUTIVE LEADERSHIP

Bonnie Anderson
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $550,000.00
Bonus: --
Keith Kennedy
Chief Financial Officer, Chief Operating Officer, Since 2019
Salary: $400,000.00
Bonus: --
Mark Ho
Principal Accounting Officer, Since 2019
Salary: --
Bonus: --
Giulia Kennedy
Chief Scientific Officer, Chief Medical Officer, Since 2018
Salary: --
Bonus: --
John Bishop
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6000 Shoreline Ct Ste 300
SOUTH SAN FRANCISCO   CA   94080-7606

Phone: +1650.2436300

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

SPONSORED STORIES